Regulatory coverage on Peptide News Digest tracks how the FDA, MHRA, EMA, and state agencies handle peptides — what they let through, what they pull, what they redefine.
The compounding fight has dominated 2025 and 2026. GLP-1s came off the FDA shortage list in early 2025; the agency moved compounded semaglutide and tirzepatide toward Category 2 on the 503A bulks list; and a wave of state legislation tried to either preserve or shut off telehealth access. The PCAC has spent meetings on BPC-157, GHK-Cu, and other research peptides that have built consumer demand without clinical infrastructure behind them.
Stories here name the agency, the substance, and the action. Browse the latest below, or jump to specific tags like #fda, #compounding, #peptide-policy, or #503a.
Following STAT News reporter Lizzy Lawrence's June 23 scoop that the FDA and Eli Lilly granted compassionate-use retatrutide access to a 79-year-old patient on the application of NIH senior clinician Dr. Ranganath Muniyappa, the White House response intensified June 23-24. Senior deputy press secretary Kush Desai posted on X that 'this application was not for the President' but did not explicitly deny that Trump (who turned 80 on June 14) had separately applied. After Lawrence reported the non-denial, Desai publicly called her 'an unserious gossip columnist.' The White House rapid response team added: 'No, it wasn't President Trump — and you people are truly sick and deranged.' The escalation moves the story from a closed regulatory-access question to an active political controversy, with outlets including The Hill, IBTimes UK, Slate, MS NOW, Hello Magazine, Tech Times, and The New Republic running parallel coverage. Outside medical experts continue to question whether refractory obesity plus OSA plus pulmonary hypertension meets the FDA's compassionate-use threshold typically reserved for immediately life-threatening illness.
The FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 at the agency's White Oak campus (Silver Spring, Maryland) reaches its first procedural cutoff next Tuesday: June 30, 2026 is the deadline to register for oral testimony in the public-comment portion of the meeting. Written comments to docket FDA-2025-N-6895 at regulations.gov must arrive by 11:59 PM ET July 22, 2026 (one day before the meeting opens). The Committee will discuss BPC-157, KPV, TB-500, and MOTS-C on Day 1 (July 23) and Emideltide/DSIP, Semax, and Epitalon on Day 2 (July 24). All seven peptides came off FDA Category 2 effective April 23, 2026. PCAC recommendations are advisory: the agency makes the final 503A bulks list decision, and the Hims & Hers (HIMS) stock breakout above $30 reflected market consensus that the July vote will tilt toward eligibility. Lengea Law and PeptideClarity have both published prescriber-facing trackers ahead of the meeting.
STAT News broke June 23, 2026 that the FDA and Eli Lilly approved a single 79-year-old patient for compassionate-use access to retatrutide (Lilly's GIP/GLP-1/glucagon triple agonist still in Phase 3 development). Dr. Ranganath Muniyappa, a senior clinician at the National Institutes of Health, submitted the application in April citing diagnoses of refractory obesity, obstructive sleep apnea, and pulmonary hypertension. Outside medical experts told STAT the diagnoses don't clearly meet the compassionate-use threshold typically reserved for immediately life-threatening illness; Jamy Ard (chief science officer, Advocate Health) said 'compassionate use is usually reserved for terminal illness.' Compassionate use programs typically serve patients facing imminent death without alternatives, not refractory obesity even with severe comorbidities. The White House had to publicly deny that President Trump submitted the application. The patient's identity has not been confirmed. The episode crystallizes the peptide-access-equity tension at a moment when the broader US population continues to source retatrutide through gray-market research-chemical channels with no oversight.
The Centers for Medicare and Medicaid Services' GLP-1 Bridge demonstration launches Wednesday July 1, 2026 — 8 days from this digest's publication — providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy injection, Wegovy pill, and Zepbound KwikPen for chronic weight management. The program runs through December 31, 2027 as a short-term bridge to the broader BALANCE Model (launching January 2027 in Medicare Part D). Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program, serves as the single central processor for prior authorization, claims adjudication, and pharmacy payment. CMS published the prior authorization fax form and prescriber/pharmacy educational materials on June 3, 2026. Eligibility requires BMI ≥30 (or ≥27 with comorbidities) and Part D enrollment. The launch arrives the same week as the Hims & Hers stock breakout and the FDA retatrutide compassionate-use disclosure — a coincidence that sharpens the peptide-access-equity debate as the broader US population continues to navigate $1,000+/month branded GLP-1 list prices.
Japan's Ministry of Health, Labour and Welfare granted Novo Nordisk a partial change approval of the manufacturing and marketing authorization for Wegovy (semaglutide) subcutaneous injection on June 19, 2026, adding an indication for metabolic dysfunction-associated steatohepatitis (MASH) without cirrhosis in patients with moderate to advanced fibrosis (stage F2 or F3). Wegovy is now the first approved MASH treatment in Japan. The approval is based on Part 1 of the global Phase 3 ESSENCE study where semaglutide 2.4 mg demonstrated statistically significant superiority to placebo on the co-primary endpoints of liver fibrosis improvement without worsening of MASH, and MASH resolution without worsening of fibrosis. Wegovy is co-promoted in Japan by Novo Nordisk Pharma and Sumitomo Pharma under the October 2025 co-promotion agreement. This is the second major MASH regulatory milestone for semaglutide after the FDA's August 2025 approval.
Australia's Therapeutic Goods Administration (TGA) escalated its peptide-products oversight to a formal compliance priority in a June 2026 media release, citing rising importation, expanding online advertising and supply, and hospitalisation data identifying serious adverse effects associated with unapproved peptides. Targeted products include BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295. The TGA emphasized that unapproved peptide products are not in the Australian Register of Therapeutic Goods and have not been evaluated for safety, quality, or efficacy. An eight-month operation involving TGA, the Australian Border Force, and Victoria Police seized about $2M worth of peptides, performance-enhancing drugs, and illicit steroids. Future compliance responses may include infringement notices, product seizures, import interventions, and civil or criminal penalties; advertising or promoting unapproved peptides through social media or influencer channels is likely to breach Australian therapeutic goods advertising laws. The escalation parallels the FDA's PCAC reclassification track and tightens the global regulatory squeeze on the gray-market peptide channel.
The Office of the U.S. Trade Representative initiated a Section 301 investigation into Germany's pricing practices for innovative pharmaceuticals on June 18, 2026, alleging that Germany's persistent underpayment for innovative pharmaceutical products is unreasonable or discriminatory and burdens or restricts U.S. commerce. The investigation focuses on Germany's 9% price discount tied to pricing confidentiality and on draft 2026 German legislation that would add a mandatory rebate on patented medicines starting in 2027. The USTR public comment docket opens June 25, with submissions due by August 10 and a hearing scheduled for September 22, 2026. The investigation extends the most-favored-nation drug-pricing pressure President Trump applied to Lilly and Novo Nordisk under the TrumpRx framework toward European pricing regimes; if USTR finds Germany's practices harm US commerce, retaliatory tariffs on German pharmaceutical exports are among the available remedies — a meaningful threat to GLP-1 supply chains given Bachem and Boehringer Ingelheim's German manufacturing footprint.
The European Medicines Agency's first-ever dedicated 'Guideline on the Development and Manufacture of Synthetic Peptides' (EMA/CHMP/CVMP/QWP/367182/2025) entered into force June 1, 2026 after adoption by CHMP on December 1, 2025 and CVMP on December 4, 2025. The guideline applies to both new and existing synthetic peptide active substances used in human and veterinary medicines, including investigational medicinal products and post-authorisation changes, and covers manufacturing routes, peptide-specific impurity types, pooling strategy in preparative chromatography, comparability requirements, characterization, specifications, and analytical control. Biological peptides produced by recombinant technology and radiopharmaceuticals are excluded. The standard arrives on the same regulatory calendar as the FDA's PCAC peptide reclassification review (July 23-24, 2026) and the FDA's 503B GLP-1 bulks exclusion comment window (closes June 29).
Wegovy and Mounjaro became reimbursable by French Health Insurance effective June 15, 2026 under orders published in the May 28, 2026 Journal Officiel. The patient co-payment rate is 35%, leaving 65% public coverage by the Sécurité Sociale. Eligibility is restricted to specific patient profiles: adults with BMI ≥30 plus a major obesity-associated comorbidity (Wegovy) or with type 2 diabetes (Mounjaro). The decision follows the UK and Switzerland in extending public insurance to GLP-1 obesity therapy, and marks a paradigm shift from 'personal responsibility' toward 'treatable disease' framing in continental European health systems. The change comes ahead of EMA Wegovy pill (oral semaglutide 25 mg) EU launches in H2 2026 following the May 22 CHMP positive opinion.
The two near-term peptide regulatory deadlines moved into the single-digit-week window on June 18. The FDA's April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list closes its 60-day comment window on June 29, after which the agency will weigh comments and issue final rulemaking; once final, the rule blocks 503B outsourcing facilities from bulk-compounding the molecules even under future shortage designation. Separately, requests to make oral presentations at the July 23-24 PCAC peptide-compounding advisory committee close June 30; the committee will weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon for 503A bulk-substances-list inclusion. Written PCAC comments remain open through July 9.
The Ohio State Board of Pharmacy released a February 18, 2026 update to its peptide compounding guidance establishing state-specific requirements that layer on top of federal 503A rules. The Ohio guidance requires all compounded peptides to be prepared pursuant to a valid patient-specific prescription from an Ohio-licensed practitioner, with detailed prescription documentation and provider-verification protocols; pharmacies cannot compound peptides on the FDA list of substances withdrawn for safety or effectiveness reasons. The guidance followed late-2025 and early-2026 enforcement actions in which at least three Ohio pharmacies received consent agreements and fines for peptide compounding violations. Together with the Alabama Board of Medical Examiners' May 26 notice prohibiting non-FDA-approved peptide prescribing, Ohio's update establishes a clear state-level enforcement pattern ahead of the July 23-24 PCAC meeting.
The Alabama Board of Medical Examiners and Medical Licensure Commission issued a formal notice on May 26, 2026 prohibiting physicians, physician assistants, certified registered nurse practitioners, and certified nurse midwives from prescribing, administering, dispensing, recommending, or supplying any non-FDA-approved research-grade peptide to a patient. The notice explicitly declares patient consent forms acknowledging research-grade status ineffective and unable to mitigate professional or legal liability. Chairman Rogers cited the lack of FDA review as the basis: substances that have not gone through FDA review cannot be reliably verified for identity, manufacturing process, or risk profile. The state-level prohibition arrived alongside the FDA's April 23 removal of 12 peptides from Category 2 ahead of the July 23-24 PCAC meeting, illustrating that state-board enforcement is now layering on top of federal regulatory action.
The FDA's April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list enters its final two weeks of public comment on June 15. The 60-day comment window closes June 29, after which the agency will weigh comments and issue final rulemaking. Once finalized, the rule will prohibit 503B outsourcing facilities from bulk-compounding these GLP-1 molecules under any circumstance, including future shortage designation. The 503A pathway through licensed pharmacies remains intact ahead of the July 23-24 PCAC peptide-compounding advisory meeting, but the trajectory for large-scale GLP-1 compounding is fixed. Telehealth platforms (Hims & Hers, LifeMD, others) had already migrated to branded supply via Novo and Lilly partnerships since Q1 2026.
Camurus said on June 10 that the FDA had issued a Complete Response Letter on the Oclaiz (CAM2029) NDA, the second the program has received and the second based solely on unresolved observations from a September 2024 cGMP inspection at a third-party contract manufacturer. The CRL did not cite clinical efficacy or safety. Camurus expects to resubmit in Q4 2026 with a second validated manufacturer; an approval pushed to the first half of 2027 leaves the US launch about a year behind the EU and UK rollouts (under the Oczyesa brand) that landed in 2025.
The Hill ran a Washington-policy framing of the July 23-24 PCAC peptide-compounding meeting, casting the agenda as the regulatory follow-through on HHS Secretary Robert F. Kennedy Jr.'s repeated pledges to ease access to wound-healing, weight-loss, and longevity peptides favored by the Make America Healthy Again movement. The committee will weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon. Written comment closes July 9; oral-presentation requests close June 30, eighteen days from today.
Novo Nordisk announced on June 11 that the UK Medicines and Healthcare products Regulatory Agency had approved the Wegovy pill (oral semaglutide tablets 25 mg) for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, making the UK the third national authority to license the molecule after the FDA and the UAE's EDE. The approval rests on the Phase 3 OASIS 4 trial, which showed about 13.6% weight loss with the 25 mg tablet versus 2% on placebo. Private-prescription availability is expected within weeks; NHS coverage requires a separate NICE cost-effectiveness appraisal.
Camurus's PDUFA target action date for Oclaiz (CAM2029), a monthly subcutaneous octreotide depot built on FluidCrystal technology, was June 10, and as of June 11 neither the FDA nor Camurus has announced an approval. The acromegaly decision sits in the unannounced-pending bucket that sometimes precedes a same-week communication. Camurus has previously said its US commercial team is launch-ready, with about 20 sales reps active and a Q3 2026 launch targeted if approved; EU and UK marketing authorizations landed in 2025.
Camurus's resubmitted NDA for Oclaiz (CAM2029), a monthly subcutaneous octreotide depot built on the company's FluidCrystal technology and delivered by autoinjector pen, carries an FDA PDUFA target action date of June 10. The resubmission, accepted in January 2026 after a Complete Response Letter tied solely to a third-party manufacturing inspection, rests on data from seven clinical studies including the two Phase 3 ACROINNOVA trials. A clearance would put Oclaiz alongside Crinetics' Palsonify (paltusotine) as the second new-mechanism acromegaly therapy in the past year, with the Camurus FluidCrystal differentiation focused on a small-volume monthly self-injection.